[Survival of patients with advanced renal carcinoma treated with interferon].
OBJECTIVE
To determine survival of patients with metastatic renal carcinoma treated with interferon.


METHODS
Retrospective longitudinal study with 18 patients with the diagnosis of metastatic renal carcinoma treated in the University Hospital Manuel Fajardo between July 2002 and September 2007 with radical surgery and alpha 2b recombinant interferon, either adjuvant or as monotherapy.


RESULTS
74% (14/18) of the patients were males, 26% (5/18) females. 72% (13/18) underwent radical surgery plus interferon, and 28% (5/18) received interferon monotherapy. Complete response was observed in 22% (4/18); 78% (14/18) had progression. One, 2, 4 and 5-year survivals were 50%, 33%, 28%, and 22%, respectively.


CONCLUSIONS
No significant response was found. There was not tumor regression in any case using interferon. Survival was better in cases undergoing radical nephrectomy plus interferon than cases treated with interferon monotherapy.
Ares Valdés
Yolanda
Y
Servicio de Urología, Hospital Universitario Manuel Fajardo, Ciudad Habana, Cuba. ares@infomed.sld.cu
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality* / Q000556:secondary; D018450:Disease Progression; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012189:Retrospective Studies; D015996:Survival Rate
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins